Objective：This study aims to analyze the characteristics of EGFR and ALK oncogenic drivers in 2 394 patients with lung adenocarcinoma，improving clinicians’ understanding of the oncogenic drivers characteristics of patients with lung adenocarcinoma in this study. Methods：From January 2014 to April 2019，2 394 patients with lung adenocarcinoma diagnosed in our hospital with concurrent EGFR and ALK detection were collected，the characteristics of EGFR and ALK oncogenic drivers were analyzed，and the correlation between EGFR/ALK status and lung adenocarcinoma subtypes was discussed. Results：59.7%（1 429/2 394）patients with lung adenocarcinoma had EGFR mutation，which was higher than the national average（51.8%）and southeast Asia（51.4%）. The mutation rate of 21L858R（48.01%）was the highest，followed by the mutation rate of 19Del（43.32%）. About 10% had rare mutations，including 18G719X，20ins and 21L861Q. The incidence of ALK rearrangement was 4.4%，lower than the national average（6.0%），and EML4-ALK fusion was the most common. The EGFR mutation rates of different types of specimens were different. The EGFR mutation rates of tissue specimens，cytology specimens and peripheral blood specimens were 60.60%，51.20% and 46.48%，respectively. Among the primary tissue specimens，the EGFR mutation rates of surgical excision specimens，percutaneous lung puncture specimens and bronchoscopy specimens were 64.50%，59.25% and 45.45%，respectively. EGFR mutations were more likely to be expressed in lepidic adenocarcinoma（79.7%），papillary adenocarcinoma（74.9%）and acinar adenocarcinoma（74.4%），and were less common in solid adenocarcinoma（58.9%）and invasive mucinous adenocarcinoma（28.9%）. ALK rearrangement rates were higher in solid adenocarcinoma（8.6%） and invasive mucinous adenocarcinoma（13.3%） than in other subtypes. Conclusion：EGFR mutation rate was higher in this study，21L858R and 19Del were the most common. The highest rate of EGFR mutation was found in the surgical excision specimens，and both EGFR mutation and ALK fusion were associated with lung adenocarcinoma subtypes.